Livingston Group Asset Management CO operating as Southport Capital Management Takes Position in Athersys, Inc. (ATHX)

Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in shares of Athersys, Inc. (NASDAQ:ATHX) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $45,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. BlackRock Inc. raised its stake in shares of Athersys by 11.6% during the fourth quarter. BlackRock Inc. now owns 7,555,866 shares of the biopharmaceutical company’s stock valued at $10,881,000 after acquiring an additional 786,445 shares during the last quarter. Vanguard Group Inc raised its stake in Athersys by 2.4% in the third quarter. Vanguard Group Inc now owns 5,707,784 shares of the biopharmaceutical company’s stock worth $11,986,000 after buying an additional 134,541 shares in the last quarter. Vanguard Group Inc. raised its stake in Athersys by 2.4% in the third quarter. Vanguard Group Inc. now owns 5,707,784 shares of the biopharmaceutical company’s stock worth $11,986,000 after buying an additional 134,541 shares in the last quarter. Geode Capital Management LLC raised its stake in Athersys by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 1,386,956 shares of the biopharmaceutical company’s stock worth $1,997,000 after buying an additional 61,106 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in Athersys by 61.7% in the third quarter. TIAA CREF Investment Management LLC now owns 461,736 shares of the biopharmaceutical company’s stock worth $970,000 after buying an additional 176,218 shares in the last quarter. Institutional investors and hedge funds own 19.76% of the company’s stock.

ATHX has been the subject of a number of research reports. ValuEngine raised shares of Athersys from a “hold” rating to a “buy” rating in a research note on Friday, January 25th. Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Wednesday, January 23rd. Finally, Maxim Group set a $8.00 price target on shares of Athersys and gave the stock a “buy” rating in a research note on Wednesday, January 23rd.

ATHX stock opened at $1.39 on Thursday. Athersys, Inc. has a 1 year low of $1.35 and a 1 year high of $3.09. The stock has a market capitalization of $211.45 million, a P/E ratio of -7.72 and a beta of 0.49.

Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. Athersys had a negative net margin of 99.96% and a negative return on equity of 49.25%. The company had revenue of $1.51 million during the quarter, compared to the consensus estimate of $0.55 million. On average, analysts anticipate that Athersys, Inc. will post -0.39 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Livingston Group Asset Management CO operating as Southport Capital Management Takes Position in Athersys, Inc. (ATHX)” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.wkrb13.com/2019/04/18/livingston-group-asset-management-co-operating-as-southport-capital-management-takes-position-in-athersys-inc-athx.html.

Athersys Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More: What is a put option?

Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.